Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $12.38

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average recommendation of “Buy” by the fourteen analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $12.6154.

A number of research firms recently issued reports on TSHA. BMO Capital Markets lifted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Pivotal Research set a $14.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday, June 24th.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $6.53 on Monday. The stock has a fifty day moving average price of $6.14 and a two-hundred day moving average price of $5.33. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The firm has a market cap of $1.88 billion, a P/E ratio of -17.18 and a beta of 1.17. Taysha Gene Therapies has a 1 year low of $2.33 and a 1 year high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Research analysts forecast that Taysha Gene Therapies will post -0.49 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the transaction, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently modified their holdings of TSHA. Marex Group plc acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new position in shares of Taysha Gene Therapies in the second quarter worth about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in shares of Taysha Gene Therapies in the third quarter worth approximately $40,000. Tower Research Capital LLC TRC increased its position in shares of Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after acquiring an additional 4,607 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.